Loading
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (1 ops.)
Latest filing published 13 Jun 2025 for Intellia Therapeutics, Inc..
Filing timeline
BuySaleFrank Verwiel
Insider track record
Disclosed buys
0
Disclosed sells
1
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
No signal scores available.
Frank Verwiel: trading record in brief
Frank Verwiel (board member) discloses dealings in 3 companies, chiefly Intellia Therapeutics, Inc., Intermune Inc and AveXis, Inc. Over a trading history stretching from 6 April 2012 to 11 June 2025, the count stands at 13 filings.
Every open-market trade on record is a sale: 1 sale worth €35k. Besides market trades, the filings include 9 share grants and 1 option exercise.
On 13 June 2025 came the latest disclosure, a share grant in Intellia Therapeutics, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Frank Verwiel
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations6 total
8,000 shares0Common StockSEC:0000950170-25-086287:0
1,505 shares@ US$25.00100.0% of flowCommon StockSEC:0000950170-24-075718:0
7,737 shares0Common StockSEC:0000950170-24-073704:0
4,425 shares0Common StockSEC:0001209191-23-037898:0
5,197 shares0Common StockSEC:0001209191-22-037604:0
2,094 shares0Common StockSEC:0001209191-21-043385:0
6 of 6 declarations
